COMMUNIQUÉS West-GlobeNewswire

EUROBIO SCIENTIFIC : MISE À DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL 2025
13/10/2025
MISE À DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL 2025 Paris, le 13 octobre 2025 – 18h30 Eurobio Scientific (FR0013240934, ALERS, éligible PEA-PME), groupe français leader dans le diagnostic médical in vitro de [...]
EUROBIO SCIENTIFIC : RAPPORT FINANCIER SEMESTRIEL AU 30 JUIN 2025
13/10/2025
EUROBIO SCIENTIFIC : RAPPORT FINANCIER SEMESTRIEL AU 30 JUIN 2025 Pièce jointe ES_Rapport_Financier_Semestriel_30062025_Final_Clean
Remix Therapeutics to Present Phase 1 Data of REM-422 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Conference in Late-Breaking Oral Presentation
13/10/2025
Study Evaluates Antitumor Activity and Safety of REM-422, a First/Best-in-Class Small Molecule MYB mRNA Degrader, in Patients with Adenoid Cystic Carcinoma WATERTOWN, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Remix [...]
Cosmos Health Purchases an Additional $300,000 in Ethereum Under Its $300 Million Digital Assets Facility; Total Investment Reaches $1.8 Million
13/10/2025
CHICAGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has purchased an [...]
Epista Launches Major Clinical Data Remediation Program with Global Pharma Leader
13/10/2025
Multi-phase initiative will remediate over 4 million clinical records across 800+ studies, ensuring inspection-ready data for global biopharma leader's digital transformation. KING OF PRUSSIA, Pa., Oct. 13, 2025 (GLOBE [...]
Neutrolis Announces Late-Breaking Oral Presentation of Clinical Results at American College of Rheumatology Convergence 2025
13/10/2025
CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Neutrolis Inc., a clinical-stage biotech company focused on targeting Neutrophil Extracellular Traps (NETs) to revolutionize the treatment of inflammatory disorders, [...]
PacBio HiFi Technology Selected as Core Platform for South Korea’s National Pangenome Project
13/10/2025
More than 1,000 Korean genomes to be sequenced for global reference standards, advancing disease research and precision medicine MENLO PARK, Calif. and SEOUL, South Korea, Oct. 13, 2025 (GLOBE NEWSWIRE) -- PacBio ( [...]
Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025
13/10/2025
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that complete data from the [...]
General Oncology to Present Preliminary Phase 1 Results from SHARON Trial in Patients with BRCA/PALB2-mutated Pancreatic and Breast Cancer at ESMO 2025
13/10/2025
BOSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- General Oncology, Inc. (“General Oncology” or the “Company”), a clinical-stage biopharmaceutical company dedicated to pioneering first-in-class medicines for metastatic cancers [...]
New Study Confirms Stress-Reduction Benefits of Natural Remedies’ Ashwa.30
13/10/2025
BANGALORE, India, Oct. 13, 2025 (GLOBE NEWSWIRE) -- A new study conducted by Clinical Research Australia reinforces the stress-reducing potential of Natural Remedies ’ Ashwa.30 , a next-generation ashwagandha extract. [...]
EarlyHealth Group acquiert CYB3R, l’entreprise de cybersécurité à la croissance la plus rapide du Golfe
13/10/2025
DUBAÏ, Émirats arabes unis, 13 oct. 2025 (GLOBE NEWSWIRE) -- EarlyHealth Group, une société internationale du secteur des services pharmaceutiques et des solutions pour les sciences de la vie, a acquis une participation [...]
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
13/10/2025
- Plenary session oral presentation: Friday, October 24 10:00 -11:40 a.m. ET - Poster presentation on preclinical evaluation of petosemtamab on cancer stem cells: Friday, October 24 12:30-4:00 p.m. ET UTRECHT, The [...]
Quanta Therapeutics Announces First Clinical Data Presentation for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
13/10/2025
RADNOR, Pa. and SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately-held clinical-stage biopharmaceutical company leading the development of innovative, oral therapeutics for [...]
Press release: Transparency Notification from Shareholder
13/10/2025
Transparency Notification from Shareholder Ghent, Belgium – 13 October 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), a pioneer in the treatment of drug-resistant fluid [...]
Avacta to Present First Dual Payload pre|CISION® Medicines Data at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets Symposium
13/10/2025
Groundbreaking oncology development with the first dual payload peptide drug conjugate platform, establishing Avacta as a leader in combination therapy innovation LONDON and PHILADELPHIA, Oct. 13, 2025 (GLOBE NEWSWIRE [...]
Artios to Announce First Phase 1/2a Data for DNA Polymerase Theta (Polθ) Inhibitor ART6043 in Advanced Solid Tumors in Oral Presentation at ESMO
13/10/2025
CAMBRIDGE, United Kingdom and NEW YORK, October 13, 2025 – Artios Pharma Limited (“Artios”), a biopharmaceutical company committed to realizing the therapeutic power of targeting the DNA damage response (“DDR”) in [...]
Together We Build: Rentschler Biopharma celebrates construction progress of new buffer media facility, largest single investment at Laupheim site
13/10/2025
Symbolic milestone for new buffer media station: Rentschler Biopharma underscores its commitment to the Laupheim headquarters and to the future of Germany and Europe as leading biotechnology hubs Shaping dialogue: Panel [...]
BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation
13/10/2025
NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) , a biopharmaceutical company pioneering the use of artificial intelligence to develop transformative medicines in [...]
Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025
13/10/2025
FRIENDSWOOD, Texas, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its [...]

Pages